Gene therapy comes of age

Science, Journal Year: 2018, Volume and Issue: 359(6372)

Published: Jan. 12, 2018

Gene therapy: The power of persistence Nearly 50 years after the concept was first proposed, gene therapy is now considered a promising treatment option for several human diseases. path to success has been long and tortuous. Serious adverse effects were encountered in early clinical studies, but this fueled basic research that led safer more efficient transfer vectors. various forms produced benefits patients with blindness, neuromuscular disease, hemophilia, immunodeficiencies, cancer. Dunbar et al. review pioneering work field its current state, describe gene-editing technologies are expected play major role field's future, discuss practical challenges getting these therapies who need them. Science , issue p. eaan4672

Language: Английский

---

The Principles of Engineering Immune Cells to Treat Cancer

Cell, Journal Year: 2017, Volume and Issue: 168(4), P. 724 - 740

Published: Feb. 1, 2017

Language: Английский

---

Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy

Cell Metabolism, Journal Year: 2017, Volume and Issue: 26(1), P. 94 - 109

Published: July 1, 2017

Language: Английский

---

Targeting of cancer neoantigens with donor-derived T cell receptor repertoires

Science, Journal Year: 2016, Volume and Issue: 352(6291), P. 1337 - 1341

Published: May 20, 2016

Outsourcing cancer immunotherapy Successful depends on a patient's T cells recognizing tumor-specific mutations and then waging lethal attack. Despite tumors harboring many mutations, most individuals have very few that respond to these so-called “neo-antigens.” Strønen et al. isolated from healthy donors responded predicted neo-antigens expressed by melanomas taken three patients, sometimes including the own ignored (see Perspective Yadav Delamarre). Testing whether such an outsourcing strategy could improve clinical outcomes will be important next step. Science , this issue p. 1337 ; see also 1275

Language: Английский

---

Acquired resistance to immunotherapy and future challenges

Nature reviews. Cancer, Journal Year: 2016, Volume and Issue: 16(2), P. 121 - 126

Published: Jan. 29, 2016

Language: Английский

---

Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy

Chemical Society Reviews, Journal Year: 2016, Volume and Issue: 45(22), P. 6250 - 6269

Published: Jan. 1, 2016

Metastasis is directly or indirectly responsible for the majority of cancer deaths. Anti-metastasis treatment thus key to cure cancer. Recent development in nanomedicine has shown great promise tackling metastasis. In recent years, nanoparticle-based drug delivery systems have been extensively explored improving treatment, showing ability reduce risk tumor metastasis compared with conventional chemotherapy. Photothermal therapy, by employing nano-theranostic agents, also found be able inhibit lymphatic Moreover, post-immunological effects certain types nano-therapies may utilized treat metastasis, presenting an exciting new avenue towards successful treatment. this review article, we would like summarize latest research advances various emerging approaches and discuss future prospects field as well clinical translation potential these techniques.

Language: Английский

---

New development in CAR-T cell therapy

Journal of Hematology & Oncology, Journal Year: 2017, Volume and Issue: 10(1)

Published: Feb. 21, 2017

Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably anti-CD19 CAR-T for acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor escape has emerged as main challenge the long-term disease control of this promising immunotherapy malignancies. In addition, success encountered significant hurdles translation solid tumors, and safety on-target/off-tumor recognition normal tissues is one reasons. mini-review, we characterize some mechanisms loss relapse new strategies address issue. discuss novel CAR designs that are being considered enhance therapy tumors.

Language: Английский

---

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Cancer Immunology Immunotherapy, Journal Year: 2017, Volume and Issue: 66(11), P. 1425 - 1436

Published: June 28, 2017

Language: Английский

---

Current status and future directions of cancer immunotherapy

Journal of Cancer, Journal Year: 2018, Volume and Issue: 9(10), P. 1773 - 1781

Published: Jan. 1, 2018

In the past decades, our knowledge about relationship between cancer and immune system has increased considerably.Recent years' success of immunotherapy including monoclonal antibodies (mAbs), vaccines, adoptive therapy checkpoint revolutionized traditional treatment.However, challenges still exist in this field.Personalized combination therapies via new techniques will be next promising strategies for future treatment direction.

Language: Английский

---

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

Cancer Cell, Journal Year: 2017, Volume and Issue: 31(3), P. 396 - 410

Published: March 1, 2017

Language: Английский

---